Judith Quinlan Joins Cytel Inc. as Vice President
Published: May 14, 2008
CAMBRIDGE, Mass., May 14 /PRNewswire/ -- Cytel Inc., a leading provider of clinical trial design services and specialized statistical software, today announced the appointment of Judith Quinlan as Vice President, Adaptive Trials.
Judith Quinlan brings over twenty years of statistical experience to the Cytel team. Prior to joining Cytel Judith spent 10 years with GSK, most recently as Statistics Director for biopharmaceuticals, and previously as Statistics Director for Neurology and GI. Throughout the last seven years she's focused on bridging the gap between new clinical research concepts and the challenging practicalities of conducting complex trials.
"Judith Quinlan has been a persistent and persuasive proponent of adaptive clinical trials both at GSK, and through her work with the PhRMA Working Group on Adaptive Designs (ADWG). This is helping pave the way toward the wide acceptance of innovative, flexible clinical study approaches. Judith combines clinical theory and practice with a strategic business perspective on Clinical Development Programs. We are very pleased, indeed, to have Judith on board," said Cytel's CEO, Ranganath Nayak.
In her new role, Judith Quinlan will guide Cytel's adaptive trial design and implementation offerings, leveraging her previous successes in managing cross-functional clinical research teams to drive more productive planning and implementation of early stage and confirmatory trials. In addition to overseeing Cytel's flourishing adaptive study efforts, Judith will continue her advocacy and education work as an active member of the PhRMA Working Group on Adaptive Designs.
A popular speaker on adaptive trial design and operations, Judith Quinlan has co-authored articles on numerous clinical research-related topics. Judith has published in such prestigious journals as Pharmacotherapy and Computational Statistics, and she co-authored with Wyeth's Mike Krams the influential PhRMA group's paper on "Implementing Adaptive Designs: Logistical and Operational Issues."
Cytel Inc. is a leading provider of clinical trial design services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets. Cytel's East(R) system is used by biostatisticians and clinicians at hundreds of companies, throughout academia and by regulators to design, simulate and monitor group sequential and adaptive clinical trials. Cytel provides trial sponsors with innovative tools, training, and consultation to increase process efficiencies and reduce development costs.
CONTACT: Michael Weitz, Director, Cytel Marketing, +1-617-661-2011,
Web site: http://www.cytel.com/